ROBERT NELSEN
CIK 1219042 · last filed 2026-06-08
ROBERT NELSEN is a corporate insider who has filed 132 SEC Form 4 insider transactions across 18 companies since 2012. The most recent filing, for PRME, was dated Jun 8, 2026. Across all open-market trades the lifetime net is +$85.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $445.6M across reported positions. 84 SEC filings were submitted jointly with KEITH CRANDELL.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$445.55M
18
132
$85.61M
Filer Profile
SUITE 1025
CHICAGO, IL 60631
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRME | Director | 6,128,297 | $2.90 | $17.77M | $43.60M | 8 | 2026-06-08 |
| SANA | Director | 12,447,375 | $2.94 | $36.66M | $10.00M | 15 | 2026-06-05 |
| LYEL | Director | 910,318 | $9.85 | $8.97M | $0 | 5 | 2024-06-17 |
| VIR | Director | 7,874,803 | $10.66 | $83.95M | $20.00M | 22 | 2024-06-03 |
| BOLD | 10%+ Owner | 1,048,433 | $2.66 | $2.79M | $12.80M | 1 | 2024-04-04 |
| NMRA | 10%+ Owner | 3,758,883 | $0.68 | $2.55M | $4.20M | 1 | 2023-09-27 |
| DNLI | Director | 9,681,181 | $20.39 | $197.40M | $0 | 8 | 2021-06-04 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | Director | 1,461,704 | $329.83 | $482.11M | $3.20M | 6 | 2021-04-15 |
| BEAM | Director | 3,535,572 | $24.27 | $85.81M | $0 | 3 | 2021-04-02 |
| Unity Biotechnology, Inc. (UBX) Delisted | Director | 168,242 | $0.20 | $33.7K | $0 | 4 | 2020-06-22 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | Director | 2,538,641 | — | — | $0 | 3 | 2018-06-05 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | 3,234 | — | — | $0 | 13 | 2018-03-07 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | 463,714 | $0.00 | $185 | $5.00M | 4 | 2017-09-22 |
| AGIO | Director | 118,404 | $32.58 | $3.86M | -$20.75M | 10 | 2017-03-07 |
| Sage Therapeutics, Inc. (SAGE) Delisted | Director | 1,232,649 | $8.68 | $10.70M | $0 | 6 | 2015-11-12 |
| KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Director | 957,604 | — | — | $0 | 8 | 2015-03-26 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | Director | 50,200 | $0.01 | $602 | $2.55M | 1 | 2015-02-23 |
| FATE | Director | 2,473,188 | $2.35 | $5.81M | $5.00M | 1 | 2013-10-07 |
Recent Filings
132 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-08 | PRME | Grant (A) | — | $0 | EDGAR |
| 2026-06-05 | SANA | Grant (A) | — | $0 | EDGAR |
| 2025-08-05 | PRME | Mixed | — | $0 | EDGAR |
| 2025-08-01 | PRME | Buy (P) | +3,030,300 | $10.00M | EDGAR |
| 2025-06-09 | SANA | Grant (A) | — | $0 | EDGAR |
| 2025-06-05 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-07-15 | SANA | Grant (A) | — | $0 | EDGAR |
| 2024-06-17 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | SANA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.